Data Describes Nimotuzumab's Unique Binding Properties Resulting In Superior Side-Effect Profile Compared To Other EGFR-Targeting Drugs - MISSISSAUGA, ON, July 21 - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that the results from research examining the binding dynamics of nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), compared to two other EGFR-targeting drugs cetuximab and panitumumab, will be presented today in a poster at the AACR Centennial Conference on Translational Cancer Medicine 2008, held in Monterey, California from July 20 - 23, 2008. The data describe the unique binding properties of nimotuzumab to EGFR that allows the...
[read full story]
Your Web Site
